CST3 and chronic kidney disease: Accurately measuring and quantifying all of these factors is both impractical and likely impossible in either well-designed research cohorts or in real-world clinical practice.14 Our findings show that obtaining a cystatin C measurement and assessing differences between eGFRcr and eGFRcys is a simple approach to distinguish risk among individuals with CKD.